No correlation between survival benefit and ERCC1 negative tumor expression was observed in a matched cohort treated with standard nCRT (p = 0.558; Figure 2A, Table S2), potentially indicating a predictive role for ERCC1 as biomarker of response to SOX. Here, ERCC1 is linked to neoplasm.